| Document |
Document Title |
|
WO/2002/076435A2 |
The invention provides use of an agent which lowers levels of 11$g(b)-HSD1 in the manufacture of a composition for the promotion of an atheroprotective lipid profile, for reducing cardiovascular disease risk, for increasing insulin sensi...
|
|
WO/2002/076390A2 |
This invention generally pertains to the field of psychiatry. In particular, this invention pertains to the discovery that agents which inhibit the binding of cortisol to its receptors can be used in methods for treating stress disorders...
|
|
WO/2002/076465A1 |
The invention relates to oleoyl-oestrone or oestrone monooleate which is a monoester of a fatty acid and of an oestrogen which is suitable for preparing a medicament for the treatment and/or prophylaxis of persons suffering from a metabo...
|
|
WO/2002/072003A2 |
The present invention relates to steroid derivatives for use as medicaments. More specifically, the invention also relates to the use of a steroid derivative of 5-androstene-, 5-pregnenolone or corresponding saturated derivatives (andros...
|
|
WO/2002/069977A1 |
The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy...
|
|
WO/2002/064614A1 |
The invention relates to novel methods for preparing 7alpha-hydroxy-dehydroepiandrosterone having formula (I):
|
|
WO/2002/062302A2 |
A compound of formula (1), wherein each of R¿1?, R¿2?, R¿4?, R¿4'?, R¿7?, R¿11?, R¿12?, R¿15?, R¿16?, R¿17'?, independently, is hydrogen, hydroxy, amino, carboxyl, oxo, halo, sulfonic acid, -O-sulfonic acid, or alkyl that is op...
|
|
WO/2002/058634A2 |
The present invention relates to analogs of estradiol, which, in their most preferred embodiment, act as locally active estrogens without significant systemic action. A series of 16$g(a)-carboxylic acid substituted steroids sand their es...
|
|
WO/2002/059139A1 |
The invention relates to 11$g(b)-halogen steroids with general formula (I), whereby R?11¿ is halogen, X-Y-Z represents a group with one of the two structures CH=C-C or CH¿2?-C=C and the other radicals have the meaning that is indicated...
|
|
WO2001010430A9 |
The present invention in various embodiments provides methods of cytoprotection and treatment of disease that include providing an enantiomer of an estrogen compound to a population of cells in a subject with a cytodegenerative condition...
|
|
WO/2002/048169A1 |
Disclosed are androgen-related steroids having a $g(D)?14¿ double bond and carrying a substituent at either or both of the carbon atoms nos. 15 and 16. The present steroids are characterized by possessing a mixed profile of androgenic a...
|
|
WO/2002/047692A1 |
Use of an oestrogen in the manufacture of a composition containing oestrogen for the treatment of atrophic vaginits in woman by administering weekly an amount of about 10- to 30 ug estradiol to a woman.
|
|
WO/2002/045719A1 |
Remedies for seasonal affective disorder containing as the active ingredient a male hormone such as testosterone or a substance promoting the secretion thereof; protective agents for hypothermia containing as the active ingredient thyroi...
|
|
WO/2002/038582A2 |
The invention relates to a method for the production of 4-(17$g(a) substituted 3-oxoestra-4,9-dien-11$g(b)-yl)benzaldehyd-(1E or 1Z)-oximes of general formula (I), where R¿1? = H, C¿1-6? alkyl or a C¿n?F¿2n+1? group; R¿2? = C¿1-4? ...
|
|
WO/2002/038581A2 |
The invention relates to a method for the production of 4-(17$g(a)-methyl substituted 3-oxoestra-4,9-dien-11$g(b)-yl)benzaldehyd-(1E or 1Z)-oximes of general formula (I), where R¿1? = H, C¿1-6? alkyl or a C¿n?F¿2n+1? group, where n =...
|
|
WO/2002/032429A2 |
The invention relates to the use of progesterone receptor inhibitors for inhibition of growth−factor−dependency of tumor cells.
|
|
WO/2002/028880A2 |
The present invention is directed to a method for treating a patient having hypertriglyceridemia comprising administering thereto a compound of the formula: I
|
|
WO/2002/026759A2 |
The invention relates to 17$g(a) fluoroalkyl steroids of the general formula (I), STEROID (I), wherein R¿3? represents a group of the formula CnFmHo, wherein n = 1, 2, 3, 4, 5 or 6, m > 1 and m+o = 2n+1. The invention further relates to...
|
|
WO/2002/026760A2 |
The invention relates to the separation of cresol from mare's urine by pervaporation by means of pore free polymer membranes made of silicon. Urine starting solutions containing qualitatively and quantitatively highly valent conjugated o...
|
|
WO/2002/022645A2 |
The present invention provides molecules, designed using the estrogen pharmacophore, that possess predicted and demonstrated estrogenic and/or estrogenic modulatory biological activity. The present invention also provides a method for ch...
|
|
WO/2002/020020A1 |
The present invention concerns the use of aromatase inhibitor exemestane, either alone or in combination with other therapeutic agents, in the chemoprevention of estrogen dependent cancer in mammals, including humans, at increased risk o...
|
|
WO/2002/017927A1 |
The present invention relates to a transdermal hydroalcoholic testosterone gel formulation that overcomes the problems associated with other testosterone delivery mechanisms by providing, among other things, a desirable pharmacokinetic h...
|
|
WO/2002/017967A1 |
The present invention relates to methods, kits, combinations, and compositions for treating, preventing or reducing the risk of developing a testosterone deficient disorder, or the symptoms associated with, or related to a testosterone d...
|
|
WO/2002/016391A1 |
Selective allylic oxidation of steroids is effectively achieved using ?t¿BuOOH in the presence of a cobalt catalyst including supported cobalt catalyst which can be easily recovered and reused.
|
|
WO/2002/016395A1 |
A composition and method of preventing or inhibiting tumor growth and, more particularly, of treating a malignant tumor, using prodrugs of plant-derived compounds and derivatives is disclosed. In the method, a composition containing betu...
|
|
WO/2002/010188A1 |
The invention makes a 16$g(a)-substituted steroidal compound available having formula 1, wherein the dotted ring is a fully saturated, a fully aromatic or a saturated ring with a $g(D)5-10 double bond; R?1¿ is (C¿1?-C¿3?)alkyl or (C¿...
|
|
WO/2002/007719A1 |
Estramustine phosphate is shown to act as an inhibitor of bone resorption and can thus be used to treat, prevent or alleviate the symptoms of bone metastasis which arise due to said bone resorption.
|
|
WO/2002/002486A1 |
A process for the preparation of polyhydric alcohols which comprises subjecting a polyhydric alcohol whose hydroxyl groups are protected to irradiation with microwave in the presence of either a basic compound or an acid exhibiting at 25...
|
|
WO/2002/002589A1 |
A compound represented by the general formula (I) useful as an antiandrogenic agent, a pharmacologically acceptable salt thereof, or a prodrug comprising either of these: (I) wherein X?1¿ and X?2¿ each independently represents hydrogen...
|
|
WO/2002/000619A2 |
Methods and compositions are provided for achieving a cytoprotective effect by selecting a polycyclic compound with a phenol group at one end of the molecule and a carbon ring at the other such that an alkyl ether functional group in whi...
|
|
WO2001058919A9 |
Syntheses of steroids such as 3-hydroxy-7 alpha -methyl-21-[2'-methoxy-4'-(diethylaminomethyl)-phenoxy]-19-n
orpregna-1,3,5(10)triene citrate ("SR 16234") and analogs thereof are provided, wherein 21-hydroxy-19-norpregna-4-en-3-one serve...
|
|
WO/2002/000225A1 |
7-Hydroxyepiandrosterone may be used for protection against acute or chronic neuronal damage.
|
|
WO/2001/097860A2 |
The present invention describes novel compounds of the formula (I):(Q)¿d?-L¿n?-C¿h?, useful for the diagnosis and treatment of cancer in combination therapy in a patient. The present invention provides novel compounds useful for the t...
|
|
WO/2001/096293A1 |
Provided are vitamin D derivatives which exhibit excellent physiologic activities suitable for drugs, particularly remedies for dermatoses such as psoriasis, and are lowered in the calcium increasing activity. The derivatives are represe...
|
|
WO/2001/084144A1 |
This invention concerns a method for in vitro determination of the activity of a drug on the activity of osteoclasts, wherein - said drug is an estrogen or a selective estrogen-receptor modulator (SERM), and - osteoclasts are cultured on...
|
|
WO/2001/077138A1 |
The present invention relates to the novel 8$g(b)-substituted estradienes of general formula (I), wherein R?2¿, R?3¿, R?6¿, R?6"¿, R?7¿, R?7"¿, R?14¿, R?15¿, R?15"¿, R?16¿, R?16"¿, R?17¿ and R?17"¿ have the meanings given in...
|
|
WO/2001/077139A1 |
The invention relates to novel 8ß-substituted estratrienes of the general formula (I), wherein R?2¿, R?3¿, R?6¿, R?6'¿, R?7¿, R?7'¿, R?9¿, R?11¿, R?11'¿, R?12¿, R?14¿, R?15¿, R?15'¿, R?16¿, R?16'¿, R?17¿ and R?17'¿ are ...
|
|
WO/2001/074366A1 |
The invention relates to the use of fulvestrant in the treatment of breast cancer in patients who have previously been treated with an Selective Estrogen Receptor Modulator (SERM) and an aromatase inhibitor.
|
|
WO/2001/074839A2 |
Methods of using 7$g(a),11$g(b)-dimethyl-17$g(b)-hydroxy-4-estren-3-one bucyclate (I) and 7$g(a),11$g(b)-dimethyl-17$g(b)-hydroxyestr-4-en-3-one 17-undecanoate (II) for various hormonal therapies, dosage forms comprising 7$g(a),11$g(b)-d...
|
|
WO/2001/068669A1 |
Novel estrogenic compounds of Formula (I) are provided, wherein the bond represented by the wavy line may be a single or double bond such that when the wavy line is a single bond, R¿1? is selected from the group consisting of hydrogen, ...
|
|
WO/2001/066561A1 |
Preventive or therapeutic drugs for eye diseases including inflammatory eye diseases, ocular hypertension, and glaucoma, which drugs contain as the active ingredient a steroid compound (I) exhibiting both a potent anti-inflammatory effec...
|
|
WO2000047603A9 |
The invention relates to novel compounds as pharmaceutical agents which have in vitro a higher affinity to estrogen receptor preparations of the rat prostate than to estrogen receptor preparations of the rat uterus and which preferably h...
|
|
WO/2001/064193A2 |
Exemestane is disclosed for use in the first-line treatment of metastatic, advanced hormone-dependent breast cancer, particularly in post-menopausal woman.
|
|
WO/2001/060376A1 |
A formulation for male contraception comprising a progestin prossessing both estrogenic and androgenic properties is remarkably effective for spermatogenesis suppression in males. The progestin Norethisterone (NET), particularly its deri...
|
|
WO/2001/060836A1 |
A process for the preparation of a 3-alkoxy- 1,3,5(10)-trien-6-one-steroid derivative having a partial structure of the general formula (2) as the moiety corresponding to the rings A and B of steroidal skeleton: (2) (wherein R is alkyl, ...
|
|
WO/2001/060375A2 |
A method is provided for treating a patient in need of therapy for acute neuronal degeneration due to metabolic compromise of central or peripheral nervous system cells comprising administering to that patient a therapeutically effective...
|
|
WO/2001/056577A1 |
A method of increasing alertness in an individual by administering an effective amount of an alertness-increasing vomeropherin to the individual; and an alarm device that, when activated, emits an alertness-increasing vomeropherin. The m...
|
|
WO/2001/052856A2 |
The invention concerns the use of at least a compound selected in the group consisting of dehydroepiandrosterone, its chemical precursors, its chemical derivatives, its biological precursors and metabolic derivatives, for preparing a com...
|
|
WO/2001/051022A1 |
The invention concerns the use of at least a compound selected in the group consisting of dehydroepiandrosterone, its precursors and its metabolic derivatives, for preparing a composition for oral administration and for use in regulating...
|
|
WO/2001/051023A1 |
The use of at least one compound selected from the group consisting of dehydroepiandrosterone, the chemical precursors thereof, the chemical derivatives thereof, the biological precursors and metabolic derivatives thereof, in the product...
|
